Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Blue Giant Acquisition Corp. has ...

Discover the latest news and updates on Roche Diagnostics with insights on their Silicon Valley campus facade.

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics , a ...

Poseida Therapeutics Inc (PSTX) stock saw a modest uptick, ending the day at $9.56 which represents a slight increase of $0.04 or 0.42% from the prior close of $9.52. The stock opened at $9.52 and ...

Piper Sandler has recently reduced Poseida Therapeutics Inc (PSTX) stock to Neutral rating, as announced on December 2, 2024, according to Finviz. Earlier, on January 4, 2023, H.C. Wainwright had ...

Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX – Get Free Report) hit a new 52-week high on Tuesday . The stock traded as ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche's wholly owned subsidiary Blue Giant Acquisition Corp. has accepted for payment all shares validly tendered and not ...

Poseida Therapeutics Stock Up 1.3 % Shares of NASDAQ PSTX opened at $9.52 on Monday. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68. The stock ...

(Alliance News) - Roche Holding AG on Wednesday said that it has completed the tender offer for all outstanding shares of Poseida Therapeutics Inc, a clinical-stage biopharmaceutical company, through ...

On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...